Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: To compare the incidence of diabetic ketoacidosis (DKA) among patients with type 2 diabetes mellitus (T2DM) who were new users of sodium glucose co‐transporter 2 inhibitors (SGLT2i) versus other classes of antihyperglycemic agents (AHAs). Methods: Patients were identified from four large US claims databases using broad (all T2DM patients) and narrow (intended to exclude patients with type 1 diabetes or secondary diabetes misclassified as T2DM) definitions of T2DM. New users of SGLT2i and seven groups of comparator AHAs were matched (1:1) on exposure propensity scores to adjust for imbalances in baseline covariates. Cox proportional hazards regression models, conditioned on propensity score‐matched pairs, were used to estimate hazard ratios (HRs) of DKA for new users of SGLT2i versus other AHAs. When I 2 <40%, a combined HR across the four databases was estimated. Results: Using the broad definition of T2DM, new users of SGLT2i had an increased risk of DKA versus sulfonylureas (HR [95% CI]: 1.53 [1.31‐1.79]), DPP‐4i (1.28 [1.11‐1.47]), GLP‐1 receptor agonists (1.34 [1.12‐1.60]), metformin (1.31 [1.11‐1.54]), and insulinotropic AHAs (1.38 [1.15‐1.66]). Using the narrow definition of T2DM, new users of SGLT2i had an increased risk of DKA versus sulfonylureas (1.43 [1.01‐2.01]). New users of SGLT2i had a lower risk of DKA versus insulin and a similar risk as thiazolidinediones, regardless of T2DM definition. Conclusions: Increased risk of DKA was observed for new users of SGLT2i versus several non‐SGLT2i AHAs when T2DM was defined broadly. When T2DM was defined narrowly to exclude possible misclassified patients, an increased risk of DKA with SGLT2i was observed compared with sulfonylureas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949 · cited 2×
“Large‐scale PS were estimated using regularized logistic regression models including all baseline covariates available from 365 days prior to the exposure index date (ie, demographics, history of all diagnoses and conditions, procedures, observations, medications, frequency of health care encounters, Charlson Comorbid…”
MethodHyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · cited 1×
“An increased risk of DKA with SGLT2 inhibitor treatment was observed in some, but not all, studies.(6,7,27,28) Limitations of prior studies include small sample size and number of events, specific patient population, and select treatment comparators.”
BackgroundInterpreting observational studies: why empirical calibration is needed to correct p‐values
Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A., & Madigan, D. (2014) · Statistics in Medicine · doi:10.1002/sim.5925 · Cited by 234
Self-citationManagement of adult diabetic ketoacidosis
Gosmanov, A. R., Gosmanova, E., & Dillard-Cannon, E. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s50516 · Cited by 223 · cited 2×
“The underlying pathophysiology of DKA is an absolute or relative insulin deficiency, increased insulin counter‐regulatory hormones, and peripheral insulin resistance.(1) DKA is often precipitated by stressful conditions such as trauma, surgery, or infection and is more common in patients with type 1 diabetes mellitus…”
Background
Cited by
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2024.7082 · Cited by 47
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Self-citation
Metadata
- Authors
- Wang, L., Voss, E. A., Weaver, J., Hester, L., Yuan, Z., DeFalco, F., Schuemie, M. J., Ryan, P. B., Sun, D., Freedman, A., Alba, M., Lind, J., Meininger, G., Berlin, J. A., & Rosenthal, N.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2019-08-27
- Volume
- 28
- Issue
- 12
- Pages
- 1620-1628
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2970896430
- Cited by
- 54
- References
- 7
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.